Characteristics and Outcomes of COVID-19-Related Hospitalization among PLWH.
COVID-19
HIV
SARS-CoV-2
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Mar 2022
11 Mar 2022
Historique:
received:
12
02
2022
revised:
04
03
2022
accepted:
08
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Background: There is conflicting evidence for how HIV influences COVID-19 infection. The aim of this study was to compare characteristics at presentation and the clinical outcomes of people living with HIV (PLWH) versus HIV-negative patients (non-PLWH) hospitalized with COVID-19. Methods: Primary endpoint: time until invasive ventilation/death. Secondary endpoints: time until ventilation/death, time until symptoms resolution. Results: A total of 1647 hospitalized patients were included (43 (2.6%) PLWH, 1604 non-PLWH). PLWH were younger (55 vs. 61 years) and less likely to be with PaO2/FiO2 < 300 mmHg compared with non-PLWH. Among PLWH, nadir of CD4 was 185 (75−322) cells/μL; CD4 at COVID-19 diagnosis was 272 cells/μL (127−468) and 77% of these were virologically suppressed. The cumulative probability of invasive mechanical ventilation/death at day 15 was 4.7% (95%CI 1.2−17.3) in PLWH versus 18.9% (16.9−21.1) in non-PLWH (p = 0.023). The cumulative probability of non-invasive/invasive ventilation/death at day 15 was 20.9% (11.5−36.4) in PLWH versus 37.6% (35.1−40.2) in non-PLWH (p = 0.044). The adjusted hazard ratio (aHR) of invasive mechanical ventilation/death of PLWH was 0.49 (95% CI 0.12−1.96, p = 0.310) versus non-PLWH; similarly, aHR of non-invasive/invasive ventilation/death of PLWH was 1.03 (95% CI 0.53−2.00, p = 0.926). Conclusion: A less-severe presentation of COVID-19 at hospitalization was observed in PLWH compared to non-PLWH; no difference in clinical outcomes could be detected.
Identifiants
pubmed: 35329872
pii: jcm11061546
doi: 10.3390/jcm11061546
pmc: PMC8953934
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute
ID : COVID-2020-12371675
Organisme : Ministero della Salute
ID : Ricerca Corrente linea 2
Références
EClinicalMedicine. 2020 Dec;29:100630
pubmed: 33200120
J Med Virol. 2021 Mar;93(3):1796-1804
pubmed: 32975842
AIDS. 2020 Nov 1;34(13):F3-F8
pubmed: 32796217
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
Clin Infect Dis. 2020 Nov 19;71(16):2294-2297
pubmed: 32472138
AIDS. 2020 Oct 1;34(12):1771-1774
pubmed: 32773476
Lancet HIV. 2020 May;7(5):e314-e316
pubmed: 32304642
Am J Epidemiol. 2021 Jan 4;190(1):10-16
pubmed: 32696057
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Clin Infect Dis. 2020 Nov 5;71(8):2021-2022
pubmed: 32459833
HIV Med. 2020 Oct;21(9):567-577
pubmed: 32671970
AIDS Patient Care STDS. 2021 Dec;35(12):457-466
pubmed: 34780305
Int J Infect Dis. 2021 Jan;102:310-315
pubmed: 33127499
J Med Virol. 2020 Nov;92(11):2387-2389
pubmed: 32462663
J Med Virol. 2020 Oct;92(10):1777-1778
pubmed: 32293709
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Clin Infect Dis. 2020 Nov 19;71(16):2276-2278
pubmed: 32407467
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
J Acquir Immune Defic Syndr. 2020 Sep 1;85(1):6-10
pubmed: 32568770
J Acquir Immune Defic Syndr. 2021 Feb 1;86(2):224-230
pubmed: 33433966
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853